Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cosmo Pharmaceuticals N.V. (COPN.SW)
CHF64.00
+0.70 (+1.11%)
IE SIX Healthcare Medical - Pharmaceuticals
Address
11, rue de Langallerie 1003
Dublin, VD, IE
Dublin, VD, IE
CEO
Giovanni di Napoli
Website
cosmopharma.com
IPO
2007-03-12
ISIN NL0011832936
Also trades on
London Stock Exchange · 0RGI.L (CHF)
Other OTC · CMOPF (USD)
Swiss Exchange · COPN.SW (CHF)
Description
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF64.00
+0.70 (+1.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
43.3K
Beta
1.48
Float Shares
8.12M
Free Float %
50.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.89% | -1.76% | -4.88% | -31.46% | +25.40% | -26.00% | +37.08% | +57.58% | -10.34% | -54.76% | +249.78% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
64.00
DCF (Unlevered)
25.12
-60.7%
DCF (Levered)
35.12
-45.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.35
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%-60.7% Q4'25: +7.0% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%-102.8% Q4'25: +75.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-8.7% Q4'25: -27.1% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-10.0% Q4'25: -8.2% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%-2.8% Q4'25: -4.7% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%-2.7% ★ Q4'25: -0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.81× ★ Q4'25: 0.49× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21.90M
est: 21.52M (+1.8%)
|
34.17M
est: 33.08M (+3.3%)
|
26.69M
est: 30.75M (-13.2%)
|
32.05M
est: 30.45M (+5.3%)
|
33.51M
est: 35.83M (-6.5%)
|
59.54M
est: 59.63M (-0.1%)
|
56.37M
est: 54.03M (+4.3%)
|
79.59M
est: 83.53M (-4.7%)
|
60.61M
est: 65.50M (-7.5%)
|
67.66M
est: 72.57M (-6.8%)
|
67.24M
est: 75.18M (-10.6%)
|
65.62M
est: 77.83M (-15.7%)
|
62.50M
est: 48.70M (+28.3%)
|
60.95M
est: 58.73M (+3.8%)
|
65.07M
est: 64.32M (+1.2%)
|
102.09M
est: 99.73M (+2.4%)
|
92.78M
est: 128.22M (-27.6%)
|
266.79M
est: 266.83M (0.0%)
|
104.85M
est: 102.22M (+2.6%)
|
116.82M
102.03M – 175.78M
+14.3% YoY
|
135.22M
93.73M – 243.08M
+15.8% YoY
|
193.06M
148.23M – 323.64M
+42.8% YoY
|
276.35M
212.18M – 463.27M
+43.1% YoY
|
405.78M
311.56M – 680.25M
+46.8% YoY
|
| EBITDA |
2.08M
est: 7.29M (-71.4%)
|
14.15M
est: 4.29M (+229.6%)
|
7.43M
est: 13.81M (-46.2%)
|
7.42M
est: 8.36M (-11.2%)
|
11.40M
est: 8.47M (+34.5%)
|
29.61M
est: 20.69M (+43.1%)
|
22.65M
est: 27.46M (-17.5%)
|
35.71M
est: 28.29M (+26.2%)
|
262.97M
est: 22.19M (+1,085.3%)
|
28.44M
est: 24.58M (+15.7%)
|
-28.81M
est: 37.51M (-176.8%)
|
-12.33M
est: -50.47M (+75.6%)
|
-7.02M
est: -5.17M (-35.7%)
|
7.84M
est: -22.30M (+135.2%)
|
17.81M
est: -27.59M (+164.6%)
|
46.74M
est: -38.67M (+220.9%)
|
19.70M
est: -51.87M (+138.0%)
|
165.71M
est: 84.79M (+95.4%)
|
2.36M
est: 32.45M (-92.7%)
|
37.09M
32.39M – 55.81M
+14.3% YoY
|
42.93M
29.76M – 77.18M
+15.8% YoY
|
61.29M
47.06M – 102.75M
+42.8% YoY
|
87.74M
67.37M – 147.09M
+43.1% YoY
|
128.83M
98.92M – 215.98M
+46.8% YoY
|
| EBIT |
622.0K
est: 5.04M (-87.7%)
|
12.55M
est: -383.4K (+3,374.0%)
|
5.73M
est: 10.39M (-44.8%)
|
5.41M
est: 4.40M (+23.1%)
|
9.18M
est: 5.65M (+62.5%)
|
27.06M
est: 14.83M (+82.5%)
|
12.94M
est: 23.98M (-46.0%)
|
22.21M
est: 20.01M (+11.0%)
|
254.48M
est: 28.76M (+784.8%)
|
27.61M
est: 17.00M (+62.5%)
|
-32.35M
est: 18.93M (-270.9%)
|
-16.81M
est: -17.10M (+1.7%)
|
-12.78M
est: -14.43M (+11.5%)
|
1.80M
est: -20.16M (+108.9%)
|
11.10M
est: -24.94M (+144.5%)
|
33.63M
est: -34.96M (+196.2%)
|
6.15M
est: -46.90M (+113.1%)
|
153.42M
est: 55.62M (+175.8%)
|
-10.48M
est: 21.29M (-149.2%)
|
24.33M
21.25M – 36.61M
+14.3% YoY
|
28.16M
19.52M – 50.63M
+15.8% YoY
|
40.21M
30.87M – 67.40M
+42.8% YoY
|
57.56M
44.19M – 96.49M
+43.1% YoY
|
84.51M
64.89M – 141.68M
+46.8% YoY
|
| Net Income |
116.0K
est: -1.15M (+110.1%)
|
9.40M
est: 184.0K (+5,008.2%)
|
4.05M
est: 8.74M (-53.7%)
|
3.61M
est: 4.01M (-10.0%)
|
7.61M
est: 4.25M (+79.1%)
|
19.32M
est: 12.65M (+52.8%)
|
68.73M
est: 17.51M (+292.6%)
|
73.32M
est: 106.26M (-31.0%)
|
248.19M
est: 53.69M (+362.2%)
|
19.34M
est: 266.30M (-92.7%)
|
-32.45M
est: 18.80M (-272.5%)
|
-18.06M
est: -35.75M (+49.5%)
|
-24.49M
est: -11.77M (-108.1%)
|
-7.90M
est: -28.33M (+72.1%)
|
21.67M
est: -35.05M (+161.8%)
|
17.23M
est: -49.13M (+135.1%)
|
-4.93M
est: -65.92M (+92.5%)
|
133.24M
est: -87.93M (+251.5%)
|
-3.63M
est: -243.7K (-1,389.9%)
|
10.27M
281.2K – 47.53M
+4,311.5% YoY
|
37.90M
7.32M – 117.51M
+269.2% YoY
|
51.74M
36.12M – 97.24M
+36.5% YoY
|
109.27M
76.28M – 205.35M
+111.2% YoY
|
327.77M
228.83M – 615.98M
+200.0% YoY
|
| SGA |
6.63M
est: 1.02M (+550.6%)
|
5.55M
est: 10.17M (-45.5%)
|
5.33M
est: 5.16M (+3.3%)
|
6.22M
est: 5.28M (+17.8%)
|
5.69M
est: 7.32M (-22.2%)
|
1.55M
est: 9.47M (-83.6%)
|
2.06M
est: 5.42M (-61.9%)
|
3.78M
est: 11.89M (-68.2%)
|
2.28M
est: 12.21M (-81.3%)
|
3.80M
est: 24.54M (-84.5%)
|
15.86M
est: 15.23M (+4.2%)
|
18.24M
est: 50.98M (-64.2%)
|
9.86M
est: 33.11M (-70.2%)
|
4.48M
est: 41.01M (-89.1%)
|
2.81M
est: 50.74M (-94.5%)
|
3.55M
est: 71.12M (-95.0%)
|
5.33M
est: 95.42M (-94.4%)
|
7.41M
est: 74.95M (-90.1%)
|
26.97M
est: 8.59M (+213.8%)
|
9.82M
8.58M – 14.78M
+14.3% YoY
|
11.37M
7.88M – 20.44M
+15.8% YoY
|
16.23M
12.46M – 27.21M
+42.8% YoY
|
23.24M
17.84M – 38.95M
+43.1% YoY
|
34.12M
26.20M – 57.19M
+46.8% YoY
|
| EPS |
0.01
est: -0.07 (+112.4%)
|
0.68
est: 0.10 (+591.0%)
|
0.30
est: 0.28 (+7.7%)
|
0.25
est: 0.26 (-4.4%)
|
0.53
est: 0.47 (+11.6%)
|
1.41
est: 1.27 (+11.3%)
|
4.81
est: 0.72 (+566.1%)
|
5.12
est: 1.60 (+220.3%)
|
17.60
est: 17.09 (+3.0%)
|
1.37
est: 1.40 (-2.0%)
|
-2.19
est: -2.26 (+3.2%)
|
-1.20
est: -1.30 (+7.6%)
|
-1.67
est: -1.66 (-0.7%)
|
-0.55
est: -0.31 (-79.9%)
|
1.29
est: 0.63 (+105.6%)
|
1.05
est: 1.17 (-10.5%)
|
-0.31
est: 1.88 (-116.5%)
|
8.15
est: 7.97 (+2.2%)
|
-0.23
est: -0.02 (-1,406.9%)
|
0.64
0.02 – 2.98
+4,311.5% YoY
|
2.37
0.46 – 7.36
+269.2% YoY
|
3.24
2.26 – 6.09
+36.5% YoY
|
6.84
4.78 – 12.86
+111.2% YoY
|
20.52
14.33 – 38.57
+200.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
191.47M
OE per share TTM
11.77
Owner's Yield
15.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
27.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 64 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.31% | 286.0K | 0.38% |
| 2 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.31% | 286.0K | 0.38% |
| 3 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.11% | 461.6K | 0.48% |
| 4 | WisdomTree International SmallCap Dividend Fund DLS | 0.11% | 1.09M | 0.58% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.08% | 273.2K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.08% | 273.2K | 0.23% |
| 7 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 435.2K | 0.40% |
| 8 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.04% | 1.45M | 0.30% |
| 9 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 67.4K | 0.41% |
| 10 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.03% | 2.26M | 0.10% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-32.3K
Shares Outstanding
16.19M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Giovanni Di Napoli | Chief Executive Officer & Director | 1M | male |
| Alessandro E. Della Cha | Non Executive Chairman | 371.8K | male |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer & Executive Director | 367.9K | male |
| Mauro Severino Ajani | Founder & Non-Executive Director | 45.7K | male |
| Luigi Longo | Chief Scientific Officer | — | male |
| Federico Sommariva | Chief Legal Counsel | — | male |
| Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices | — | male |
| Davide Malavasi | Qualified Person & Technical Director | — | male |
| Silvia Miliani | Chief HR Officer | — | female |
| Svetlana Sigalova | Chief Financial Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COPN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
